Theratechnologies (TSE:TH) Given New C$7.00 Price Target at National Bank Financial

Theratechnologies (TSE:TH) had its price objective lowered by National Bank Financial from C$8.25 to C$7.00 in a research report sent to investors on Wednesday, BayStreet.CA reports. National Bank Financial currently has a sector perform rating on the stock. National Bank Financial also issued estimates for Theratechnologies’ FY2020 earnings at $0.27 EPS.

Other equities research analysts have also recently issued research reports about the stock. Mackie reduced their target price on shares of Theratechnologies from C$8.15 to C$7.00 and set a hold rating for the company in a research note on Friday, July 12th. Royal Bank of Canada reduced their target price on shares of Theratechnologies from C$7.00 to C$6.00 and set a sector perform rating for the company in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of C$8.75.

TSE TH opened at C$4.90 on Wednesday. The company has a debt-to-equity ratio of 167.71, a quick ratio of 1.94 and a current ratio of 2.51. The firm has a 50-day simple moving average of C$5.35 and a 200 day simple moving average of C$6.27. Theratechnologies has a twelve month low of C$4.71 and a twelve month high of C$9.74. The stock has a market cap of $377.07 million and a PE ratio of -55.06.

Theratechnologies (TSE:TH) last released its earnings results on Thursday, July 11th. The company reported C($0.06) earnings per share for the quarter. The company had revenue of C$20.92 million for the quarter, compared to analyst estimates of C$26.00 million. Research analysts forecast that Theratechnologies will post 0.07 earnings per share for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Featured Story: What is Elliott Wave theory?

Analyst Recommendations for Theratechnologies (TSE:TH)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.